US Stock Market Move | Q3 performance better than expected, United Therapeutics Corporation (UTHR.US) surges over 12%

On Wednesday, United Therapeutics Corporation (UTHR.US) surged over 12%, hitting a new all-time high of $465.38. On the news front, on October 29, the company announced its third-quarter performance for 2025, with earnings per share of $7.16, surpassing analyst expectations by about $0.16, and net profit reaching $338.7 million, a year-on-year increase of about 9.6%. The main product Tyvaso reported continued double-digit growth, driving total revenue to a record $799.5 million, a 7% increase compared to the same period last year, reflecting strong market demand.